Oxford Cannabinoid Technologies Holdings' Valentino Parravicini joins Proactive to talk about the significance of appointing clinical research organisation (CRO) Simbec-Orion.
He says it is an 'important milestone' to partner up with Simbec-Orion for the first-in-human Phase 1 clinical trial of its lead compound, OCT46120.